整合影像组学与转录组学揭示非小细胞肺癌亚型特征
本研究纳入三个数据集共627例非小细胞肺癌患者,从三维肿瘤分割体积提取影像组学特征,结合转录组学通路与免疫细胞富集评分,通过共识聚类识别出三种放射转录组亚型(RTS1增殖型、RTS2代谢型、RTS3免疫激活型)。RTS分层策略在验证队列中显示显著预后价值(p=0.009),校正临床参数后仍为独立预后指标。
要点
- 基于影像组学与通路富集评分可无创划分NSCLC为三种放射转录组亚型。
- RTS3为免疫激活亚型,多数免疫细胞浸润增加。
- RTS分层可独立于临床参数预测NSCLC预后。
关键影像表现/征象
- RTS1为增殖亚型,RTS2为代谢亚型,RTS3为免疫激活亚型,各具特定分子标志。
- RTS3显示多数免疫细胞浸润增加。
- 亚型特异性影像组学特征用于验证聚类性能与预后价值。
诊断标准与关键数值
- 基于影像组学特征与通路富集评分的共识聚类将NSCLC分为三个放射转录组亚型(RTS1、RTS2、RTS3)。
- RTS分层策略在验证队列中显示显著预后价值,生存分析p=0.009。
- 校正其他临床参数后,RTS策略仍为独立预后指标。
临床应用与阅片要点
- 阅片时可关注与RTS亚型相关的影像组学特征,辅助无创推断分子表型。
- RTS3免疫激活亚型可能提示免疫细胞浸润较多,可供临床参考。
- RTS分层有助于识别预后较差患者,支持风险分层。
局限性
- 原文未明确报告研究是否为单中心或回顾性设计。
- 影像组学特征提取依赖三维肿瘤分割,分割差异可能影响结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To assess whether integrative radiomics and transcriptomics analyses could provide novel insights for radiomic features' molecular annotation and effective risk stratification in non-small cell lung cancer (NSCLC).
METHODS: A total of 627 NSCLC patients from three datasets were included. Radiomics features were extracted from segmented 3-dimensional tumour volumes and were z-score normalized for further analysis. In transcriptomics level, 186 pathways and 28 types of immune cells were assessed by using the Gene Set Variation Analysis (GSVA) algorithm. NSCLC patients were categorized into subgroups based on their radiomic features and pathways enrichment scores using consensus clustering. Subgroup-specific radiomics features were used to validate clustering performance and prognostic value. Kaplan-Meier survival analysis with the log-rank test and univariable and multivariable Cox analyses were conducted to explore survival differences among the subgroups.
RESULTS: Three radiotranscriptomics subtypes (RTSs) were identified based on the radiomics and pathways enrichment profiles. The three RTSs were characterized as having specific molecular hallmarks: RTS1 (proliferation subtype), RTS2 (metabolism subtype), and RTS3 (immune activation subtype). RTS3 showed increased infiltration of most immune cells. The RTS stratification strategy was validated in a validation cohort and showed significant prognostic value. Survival analysis demonstrated that the RTS strategy could stratify NSCLC patients according to prognosis (p = 0.009), and the RTS strategy remained an independent prognostic indicator after adjusting for other clinical parameters.
CONCLUSIONS: This radiotranscriptomics study provides a stratification strategy for NSCLC that could provide information for radiomics feature molecular annotation and prognostic prediction.
KEY POINTS: • Radiotranscriptomics subtypes (RTSs) could be used to stratify molecularly heterogeneous patients. • RTSs showed relationships between molecular phenotypes and radiomics features. • The RTS algorithm could be used to identify patients with poor prognosis.
引用
- Lin, Lin, Gao, et al. Integrative radiomics and transcriptomics analyses reveal subtype characterization of non-small cell lung cancer. Eur Radiol. 2023. PMID: 36826501. doi:10.1007/s00330-023-09503-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。